IP Verse

Use Of Erbb3 Inhibitors In The Treatment Of Triple Negative And Basal-Like Breast Cancers

Patent No. EP2544680 (titled "Use Of Erbb3 Inhibitors In The Treatment Of Triple Negative And Basal-Like Breast Cancers") was filed by Merrimack Pharmaceuticals on Mar 11, 2011. The application was issued on Jan 14, 2015.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
DAIICHI SANKYOOct 13, 2015HOFFMANN EITLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2544680

MERRIMACK PHARMACEUTICALS
Application Number
EP11730112A
Filing Date
Mar 11, 2011
Status
Revoked
Aug 27, 2021
Publication Date
Jan 14, 2015
External Links
Slate, Register , Google Patents